Trikafta (elexacaftor/tezacaftor/ivacaftor) Letter of Medical Necessity
Trikafta (elexacaftor/tezacaftor/ivacaftor) is the standard of care for cystic fibrosis patients with at least one F508del mutation. PA requires CFTR genotyping confirmation and baseline lung function documentation.
FDA-Approved Indications
- ● cystic fibrosis in patients ≥2 years with at least one F508del-CFTR mutation
Why Trikafta Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. CFTR genotype not documented
- 2. Baseline pulmonary function testing (FEV1) missing
- 3. LFT monitoring plan not specified
- 4. Age criteria not met
- 5. Prior CFTR modulator trial not documented
What to Include in a Trikafta Letter of Medical Necessity
Document CF diagnosis with sweat chloride or genetic confirmation, specific CFTR genotype with at least one F508del mutation, baseline FEV1 percent predicted, baseline LFTs, current CF care regimen, and the monitoring plan for hepatic function during therapy.
Key clinical evidence to cite:
- ✓ VX-445-102 and VX-445-104 (F508del homozygous and heterozygous)
- ✓ VX-445-106 (ages 6-11)
- ✓ VX-445-116 (ages 2-5)
- ✓ Real-world registry data showing sustained FEV1 improvement
Relevant guidelines:
- 📖 CFF CFTR Modulator Therapy Guidelines
- 📖 CFF Pulmonary Clinical Practice Guidelines
Trikafta Prior Authorization Criteria
Standard criteria across major US payers for Trikafta. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Prior CFTR modulator trial not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Trikafta
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Trikafta Prior Authorization FAQ
Why was my Trikafta prior authorization denied?
The most common denial reasons for Trikafta are: CFTR genotype not documented; Baseline pulmonary function testing (FEV1) missing; LFT monitoring plan not specified; Age criteria not met; Prior CFTR modulator trial not documented.
What should a Trikafta Letter of Medical Necessity include?
Document CF diagnosis with sweat chloride or genetic confirmation, specific CFTR genotype with at least one F508del mutation, baseline FEV1 percent predicted, baseline LFTs, current CF care regimen, and the monitoring plan for hepatic function during therapy.
Which payers cover Trikafta?
Trikafta is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part D, though formulary tier and prior authorization criteria vary.